Myeloid-derived suppressor cells (MDSCs): what do we currently know about the effect they have against anti-PD-1/PD-L1 therapies?

5 Jun 2023
Ronald Sergio Limón Tellez, Lucia Reynolds, Miguel A Piris

Recent advances in cancer treatment such as PD-1/PD-L1 checkpoint inhibitors have prompted multiple research studies to determine all of the factors that influence response or failure to these new treatments. One of those identified factors is myeloid-derived suppressor cells (MDSCs). These cells were identified and described for the first time in 2007 in laboratory mice and cancer patients. Previous studies showed that a greater number of MDSCs was directly related to a greater tumour volume. There are two clearly identified subpopulations: Mononuclear-type myeloid-derived suppressor cells (M-MDSCs) and polymorphonuclear (PMN-MDSCs). These cell population subtypes play a very important role, depending on the type of cancer, since they have the particularity of expressing PD-L1, which interacts with PD-1, inhibiting the expansion of cytotoxic T lymphocytes, promoting resistance to these treatments.

Related Articles

Uchenna Simon Ezenkwa, Gabriel Olabiyi Ogun, Mbwas Isaac Mashor, Olufemi John Ogunbiyi
Zoya Peelay, Deevyashali Parekh, Vijay M Patil, Vanita Noronha, Nandini Menon, Kumar Prabhash
Rodrigo Motta Guerrero, Veronica Arnao Labajos, Sophia Lozano Ballena, Carlos Aliaga Macha, Miguel Sotelo Lezama, Cristian Pacheco Roman, Paola Montenegro Beltran, Alejandro Figueroa Torrejon
Vijay Patil, George Abraham, Madala Ravikrishna, Atanu Bhattacharjee, Vanita Noronha, Deevyashali Parekh, Nandini Menon, Jyoti Bajpai, Kumar Prabhash